Literature DB >> 16153729

Costing the components of pain management: analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): one versus five fractions for neuropathic bone pain.

Christine A Pollicino1, Sandra L Turner, Daniel E Roos, Peter C O'Brien.   

Abstract

BACKGROUND AND
PURPOSE: Bone metastases causing neuropathic pain (NBP) have traditionally been treated with fractionated radiotherapy (RT). A recently reported randomised Trans-Tasman Radiation Oncology Group trial (TROG 96.05) supports this approach in many cases [Roos DE, Turner SL, O'Brien PC et al. Randomised trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol 2005;75:54-63]. This study sought to compare costs to the Australian health-care system for patients receiving 1 versus 5 fractions for NBP. PATIENTS AND METHODS: The RT and medication costs for 245 patients treated on TROG 96.05 were determined from trial data out to 3 months from RT. Admission costs and causes were derived from hospital records.
RESULTS: RT costs (including re-treatments) were calculated to be 222 and 724 Australian dollars (A dollars) per patient for the 8 Gy/1 and 20 Gy/5 arms, respectively. This difference increased when analgesics (A dollars 192 versus A dollars 229) and related hospital admissions (A dollars 1,411 versus A dollars 1,893) were considered. Sensitivity analysis demonstrated an incremental cost saving of between A dollars 795 and A dollars 1,468 for single fraction RT. Admission rates had the strongest potential to distort cost differences.
CONCLUSIONS: Clinical outcomes are paramount in choice of fractionation scheme but are optimally considered in the light of economic implications. Overall cost differences between fractionation schedules may vary greatly from those incurred by the RT treatment centre alone. Ideally, such economic evaluations should be planned at the outset of a trial.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16153729     DOI: 10.1016/j.radonc.2005.07.003

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

Review 1.  Palliative radiotherapy for bone metastases from lung cancer: Evidence-based medicine?

Authors:  Alysa Fairchild
Journal:  World J Clin Oncol       Date:  2014-12-10

2.  A Palliative Radiation Oncology Consult Service Reduces Total Costs During Hospitalization.

Authors:  Sanders Chang; Peter May; Nathan E Goldstein; Juan Wisnivesky; Doran Ricks; David Fuld; Melissa Aldridge; Kenneth Rosenzweig; Rolfe Sean Morrison; Kavita V Dharmarajan
Journal:  J Pain Symptom Manage       Date:  2018-03-08       Impact factor: 3.612

3.  Does dissemination of guidelines alone increase the use of palliative single-fraction radiotherapy? Initial report of a longitudinal change management campaign at a provincial cancer program.

Authors:  J O Kim; N Hanumanthappa; Y T Chung; J Beck; R Koul; B Bashir; A Cooke; A Dubey; J Butler; M Nashed; W Hunter; A Ong
Journal:  Curr Oncol       Date:  2020-08-01       Impact factor: 3.677

Review 4.  Single fraction radiotherapy versus multiple fraction radiotherapy for bone metastases in prostate cancer patients: comparative effectiveness.

Authors:  Frederick Yoon; Gerard C Morton
Journal:  Cancer Manag Res       Date:  2014-11-25       Impact factor: 3.989

5.  STAT-ART: The Promise and Practice of a Rapid Palliative Single Session of MR-Guided Online Adaptive Radiotherapy (ART).

Authors:  Kathryn E Mittauer; Patrick M Hill; Mark W Geurts; Anna-Maria De Costa; Randall J Kimple; Michael F Bassetti; John E Bayouth
Journal:  Front Oncol       Date:  2019-10-22       Impact factor: 6.244

6.  Do Sustainable Palliative Single Fraction Radiotherapy Practices Proliferate or Perish 2 Years after a Knowledge Translation Campaign?

Authors:  Shaheer Shahhat; Nikesh Hanumanthappa; Youn Tae Chung; James Beck; Rashmi Koul; Bashir Bashir; Andrew Cooke; Arbind Dubey; Jim Butler; Maged Nashed; William Hunter; Aldrich D Ong; Shrinivas Rathod; Kim Tran; Julian O Kim
Journal:  Curr Oncol       Date:  2022-07-19       Impact factor: 3.109

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.